Cargando…

Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer

INTRODUCTION: Injectable GnRH receptor agonists have been shown to improve cancer control when combined with radiotherapy. Prostate SBRT offers an abbreviated treatment course with comparable efficacy to conventionally fractionated radiotherapy. Relugolix is a new oral GnRH receptor antagonist which...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gallagher, Lindsey, Xiao, Jerry, Hsueh, Jessica, Shah, Sarthak, Danner, Malika, Zwart, Alan, Ayoob, Marilyn, Yung, Thomas, Simpson, Tiffany, Fallick, Mark, Kumar, Deepak, Leger, Paul, Dawson, Nancy A., Suy, Simeng, Collins, Sean P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616590/ https://www.ncbi.nlm.nih.gov/pubmed/37916156 http://dx.doi.org/10.3389/fonc.2023.1289249

Ejemplares similares

Bleeding Risk Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer in Men on Baseline Anticoagulant or Antiplatelet Therapy
por: Pepin, Abigail, et al.
Publicado: (2021)

Treatment Interruptions During Stereotactic Body Radiotherapy for Prostate Cancer
por: Pepin, Abigail N., et al.
Publicado: (2022)

Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?
por: Kataria, Shaan, et al.
Publicado: (2017)

Utilization of Patient-Reported Outcomes to Guide Symptom Management during Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer
por: Danner, Malika, et al.
Publicado: (2017)

Impact of Age on Patient-Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Pepin, Abigail, et al.
Publicado: (2021)

Management of Isolated Local Failures Following Stereotactic Body Radiation Therapy for Low to Intermediate Risk Prostate Cancer
por: Aghdam, Nima, et al.
Publicado: (2020)

Self-Reported Burden in Elderly Patients With Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT)
por: Aghdam, Nima, et al.
Publicado: (2020)

The Impact of Obesity on Patient Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Koneru, Harsha, et al.
Publicado: (2016)

Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP)
por: Pepin, Abigail, et al.
Publicado: (2020)

Ten-Year Single Institutional Analysis of Geographic and Demographic Characteristics of Patients Treated With Stereotactic Body Radiation Therapy for Localized Prostate Cancer
por: Aghdam, Nima, et al.
Publicado: (2021)

Patient-Reported Financial Burden Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer
por: Sholklapper, Tamir N., et al.
Publicado: (2022)

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS ≥ 15)
por: Aghdam, Nima, et al.
Publicado: (2020)

Association of baseline self-reported fatigue with overall survival after stereotactic body radiation therapy for localized prostate cancer
por: Simhal, Rishabh K., et al.
Publicado: (2022)

A Randomized Open-Label Study of Relugolix Alone or Relugolix Combination Therapy in Premenopausal Women
por: Lukes, Andrea, et al.
Publicado: (2023)

Bothersome Hematospermia Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Shah, Sarthak, et al.
Publicado: (2021)

Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer
por: Shore, Neal D., et al.
Publicado: (2023)

Testosterone as a Biomarker for Quality of Life (QOL) Following Androgen Deprivation Therapy (ADT) and Stereotactic Body Radiotherapy (SBRT)
por: Shah, Sarthak, et al.
Publicado: (2023)

Relugolix: A Review in Advanced Prostate Cancer
por: Shirley, Matt
Publicado: (2023)

Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
por: Ju, Andrew W, et al.
Publicado: (2013)

A case of lichenoid drug eruption associated with relugolix
por: Han, Joseph, et al.
Publicado: (2023)

Correction to: Relugolix: A Review in Advanced Prostate Cancer
por: Shirley, Matt
Publicado: (2023)

Relugolix – The novel oral androgen deprivation therapy for prostate cancer
por: Jena, Rahul
Publicado: (2020)

Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas
por: Al-Hendy, Ayman, et al.
Publicado: (2022)

A case of adenomyosis with leiomyoma that was effectively treated with relugolix and kamishoyosan add-on therapy
por: Sasamori, Yukifumi, et al.
Publicado: (2021)

Relugolix: A new kid on the block among gonadotrophin-releasing hormone antagonists
por: Fragkoulis, Charalampos, et al.
Publicado: (2021)

Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids
por: Syed, Yahiya Y.
Publicado: (2022)

Characteristics of submucosal leiomyomas that could cause severe hemorrhage with relugolix: an observational study
por: Wada, Yoshimitsu, et al.
Publicado: (2023)

Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases
por: Brown, Gordon, et al.
Publicado: (2022)

A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy
por: Kasparian, Saro, et al.
Publicado: (2023)

Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy
por: Carrasquilla, Michael, et al.
Publicado: (2021)

Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial
por: Hoshiai, Hiroshi, et al.
Publicado: (2021)

Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer
por: Saad, Fred, et al.
Publicado: (2021)

Relugolix as a promising novel oral GnRH antagonist for prostate cancer treatment
por: Lv, Jialu, et al.
Publicado: (2020)

An Efficient UPLC-MS/MS Method Established to Detect Relugolix Concentration in Rat Plasma
por: Xing, Liying, et al.
Publicado: (2022)

Correction: Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids
por: Syed, Yahiya Y.
Publicado: (2022)

Rationale for Stereotactic Body Radiation Therapy in Treating Patients with Oligometastatic Hormone-Naïve Prostate Cancer
por: Bhattasali, Onita, et al.
Publicado: (2013)

Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis
por: Arjona Ferreira, Juan C., et al.
Publicado: (2022)

A plain language summary of the long-term relugolix combination therapy study for uterine fibroids
por: Al-Hendy, Ayman, et al.
Publicado: (2023)

Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy
por: Tatenuma, Tomoyuki, et al.
Publicado: (2023)

Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3))
por: Janowski, Einsley, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_s4egc8hnct9nlhl074lduhe2qb